NEW YORK, Sept. 18, 2024 /PRNewswire/ -- Rosen Law Firm, a global investor rights law firm, announces the filing of a class action lawsuit on behalf of purchasers of securities of Allarity Therapeutics, Inc. (NASDAQ: ALLR) between May 17, 2022 and July 19, 2024, both dates inclusive (the "Class Period"). A class action lawsuit has already been filed. If you wish to serve as lead plaintiff, you must move the Court no later than November 12, 2024.So what: If you purchased Allarity securities during the Class ...

NEW YORK, Sept. 17, 2024 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized stockholder rights law firm, announces that a class action lawsuit has been filed against Allarity Therapeutics, Inc. (“Allarity” or the “Company”) (NASDAQ: ALLR) in the United States District Court for the Southern District of New York on behalf of all persons and entities who purchased or otherwise acquired Allarity securities between May 17, 2022 and July 19, 2024, both dates inclusive (the “Class Period”). ...

Investors can contact the law firm at no cost to learn more about recovering their losses LOS ANGELES, Sept. 17, 2024 (GLOBE NEWSWIRE) -- The Portnoy Law Firm advises Allarity Therapeutics, Inc. ("Allarity" or the "Company") (NASDAQ: ALLR) investors of a class action representing investors that bought securities between May 17, 2022, and July 19, 2024, inclusive (the "Class Period"). Allarity investors have until November 12, 2024 to file a lead plaintiff motion. Investors are encouraged to contact attorney ...

NEW YORK, Sept. 17, 2024 (GLOBE NEWSWIRE) -- Attorney Advertising -- Bronstein, Gewirtz & Grossman, LLC, a nationally recognized law firm, notifies investors that a class action lawsuit has been filed against Allarity Therapeutics, Inc. (“Allarity” or “the Company”) (NASDAQ: ALLR) and certain of its officers. Class Definition This lawsuit seeks to recover damages against Defendants for alleged violations of the federal securities laws on behalf of all persons and entities that purchased or otherwise acquire ...

SAN DIEGO, Sept. 16, 2024 (GLOBE NEWSWIRE) -- Robbins LLP informs investors that a shareholder filed a class action on behalf of all persons and entities who purchased or otherwise acquired Allarity Therapeutics, Inc. (NASDAQ: ALLR) securities between May 17, 2022 and July 19, 2024. Allarity is a clinical-stage biopharmaceutical company that develops oncology therapeutics using drug-specific companion diagnostics generated by its Drug Response Predictor technology. For more information, submit a form, email ...

NEW YORK, Sept. 16, 2024 (GLOBE NEWSWIRE) -- Gainey McKenna & Egleston announces that a securities class action lawsuit has been filed in the United States District Court for the Southern District of New York on behalf of all persons or entities who purchased or otherwise acquired Allarity Therapeutics, Inc. (“Allarity” or the “Company”) (NASDAQ: ALLR) securities between May 17, 2022 and July 19, 2024, inclusive (the “Class Period”). The lawsuit seeks to recover damages for the Company’s investors under the ...

ATLANTA, Sept. 16, 2024 (GLOBE NEWSWIRE) -- A shareholder class action lawsuit has been filed against Allarity Therapeutics, Inc. (“Allarity” or the “Company”) (NASDAQ: ALLR). The lawsuit alleges that Defendants made false and/or misleading statements and/or failed to disclose material information regarding the Company’s business, operations, and compliance policies, including allegations that: (i) Defendants had overstated the Dovitinib new drug application’s (“NDA”) continued regulatory prospects; (ii) Al ...

财务状况和资金需求 - 公司通过场外发行筹集了2,768.9万美元资金,截至2024年6月30日现金及现金等价物为1,920万美元[167][169] - 公司目前有足够资金维持当前运营和计划资本支出,但未来仍需要通过发行证券或其他方式筹集资金[169] - 公司预计未来将需要大量资金用于药品研发和商业化,但目前无法准确估算具体金额[171] - 公司正计划在近期进行公开增发,但无法保证一定能成功筹集到所需的流动资金,如果无法筹集到资金可能会对公司的业务、经营业绩和财务状况产生负面影响[170] - 公司目前认为现有现金和现金等价物足以支持未来12个月的预期支出和承诺,但实际情况可能与假设不同,公司可能需要更快地消耗资本[178] 经营活动和现金流 - 2024年上半年,公司经营活动产生的现金流出较2023年同期增加300万美元,主要是由于非现金经营费用增加89万美元以及经营性资产减少现金2.8百万美元,但亏损减少66万美元[175] - 2024年上半年,公司筹资活动产生的现金流入增加2.37亿美元,主要是由于发行普通股收到2.77亿美元净额[176,177] 会计政策和披露 - 公司的关键会计政策和重大判断及估计在2024年上半年未发生重大变化[180,181] - 公司已披露了最近采用和尚未采用的会计准则变更[182] - 公司属于较小报告公司,无需提供市场风险的定量和定性披露[183] 经营风险 - 公司正在应对纳斯达克摘牌的风险,已于2024年6月27日获得听证会[142][143] - 公司收到美国证券交易委员会的调查通知,涉及2021年提交的药品新药申请[145] - 公司在正常业务过程中与供应商签订了一些可随时取消的合同,因此认为这些合同项下的不可取消义务并不重大[172] 研发和管理费用 - 研发费用增加主要是由于制造和供应费用增加442,000美元、研究费用增加317,000美元、里程碑付款增加100,000美元[157][158] - 管理费用下降主要是由于保险费用下降495,000美元、融资费用下降380,000美元、财务顾问费用下降395,000美元[160][161] 股票变动 - 公司于2024年4月9日进行了1:20的股票合并[144]

文章核心观点 - 美国证券交易委员会(SEC)向Allarity Therapeutics公司发出了"Wells通知",指控公司在与美国食品药品监督管理局(FDA)关于Dovitinib新药申请的会议披露方面存在违反联邦证券法的行为 [4][5] - SEC还向公司3名前高管发出了Wells通知,涉及同样的行为 [5] - Rosen律师事务所正在准备针对Allarity Therapeutics公司的集体诉讼,寻求投资者损失的赔偿 [1][2][3] 公司概况 - Allarity Therapeutics公司是一家生物制药公司,主要从事新药研发 [4][5] - 公司之前曾就Dovitinib新药申请与FDA进行过会议 [5] 监管调查 - SEC对Allarity Therapeutics公司及其3名前高管展开调查,指控公司在与FDA会议披露方面存在违法行为 [4][5] - SEC向公司及高管发出了Wells通知,表示有初步决定提起执法行动的意向 [5] 投资者诉讼 - Rosen律师事务所正在准备针对Allarity Therapeutics公司的集体诉讼,寻求投资者损失的赔偿 [1][2][3] - 投资者可以通过Rosen律师事务所的网站或电话加入集体诉讼 [3] 律所介绍 - Rosen律师事务所是一家专注于证券集体诉讼的全球性投资者权益律所 [6] - 该所在证券集体诉讼领域拥有丰富的从业经验和成功案例,曾获得多项行业荣誉 [6]

NEW YORK, Aug. 2, 2024 /PRNewswire/ -- Wolf Haldenstein Adler Freeman & Herz LLP ("Wolf Haldenstein"), a preeminent national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors in Allarity Therapeutics, Inc. (NASDAQ: ALLR) ("Allarity" or "the Company").The investigation focuses on whether the Company issued false and/or misleading statements and/or did not disclose information pertinent to investors.PLEASE CLICK HERE TO PROVIDE YOUR CONTACT INFORMATIONOn July ...